Active	Status	Sponsor type	Region	Phase	Filter
9 Active 1 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Slevin, John T
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
NCT06006247: Early Parkinson's Disease Monotherapy With CVN424	Active, not recruiting	2	62	US	CVN424 150 mg, Placebo	Cerevance Beta, Inc.	Parkinson's Disease	10/24	02/25
Wagner, Renee
ORION, NCT06122662: AMX0035 and Progressive Supranuclear Palsy	Active, not recruiting	2/3	110	Europe, US	AMX0035, Placebo	Amylyx Pharmaceuticals Inc.	Progressive Supranuclear Palsy, PSP, Neurodegenerative Diseases, Atypical Parkinsonism	04/26	11/29
ACTIVATE, NCT05819359: Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD	Active, not recruiting	2	237	Europe, Canada, US	BIA 28-6156 10 mg, BIA 28-6156 60 mg, Placebo	Bial R&D Investments, S.A.	Parkinson's Disease	03/26	07/26